Trial · NCT00112723
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Disease-specific Dose-limiting Toxicity and Maximum Tolerated Dose of Flavopiridol Graded According to the CTCAE (Common Toxicity Criteria for Adverse Effects) Version 4.0 (Phase I) | Dose Level 1 (Flavopiridol 30 mg/m2 + 30 mg/m2) | 0 | patients | ||
| Disease-specific Dose-limiting Toxicity and Maximum Tolerated Dose of Flavopiridol Graded According to the CTCAE (Common Toxicity Criteria for Adverse Effects) Version 4.0 (Phase I) | Dose Level 2 (Flavopiridol 30 mg/m2 + 50 mg/m2) | 0 | patients | ||
| Disease-specific Dose-limiting Toxicity and Maximum Tolerated Dose of Flavopiridol Graded According to the CTCAE (Common Toxicity Criteria for Adverse Effects) Version 4.0 (Phase I) | Dose Level 3 (Flavopiridol 50 mg/m2 + 50 mg/m2) | 0 | patients | ||
| Maximum Tolerated Dose (MTD) | Dose Level 1 (30+30) | 60 | mg/m2 | ||
| Maximum Tolerated Dose (MTD) | Level 2 (30+50) | 80 | mg/m2 | ||
| Maximum Tolerated Dose (MTD) | Level 3 (50+50) | 100 | mg/m2 | ||
| Complete and Partial Response Rate (Phase II) | Dose Level 1 (Flavopiridol 30 mg/m2 + 30 mg/m2) | Complete Response | 0 | patients | |
| Complete and Partial Response Rate (Phase II) | Dose Level 2 (Flavopiridol 30 mg/m2 + 50 mg/m2) | Complete Response | 0 | patients | |
| Complete and Partial Response Rate (Phase II) | Dose Level 3 Dose (Flavopiridol 50 mg/m2 + 50 mg/m2) | Complete Response | 0 | patients | |
| Complete and Partial Response Rate (Phase II) | Dose Level 1 (Flavopiridol 30 mg/m2 + 30 mg/m2) | Partial Response | 2 | patients | |
| Complete and Partial Response Rate (Phase II) | Dose Level 2 (Flavopiridol 30 mg/m2 + 50 mg/m2) | Partial Response | 2 | patients | |
| Complete and Partial Response Rate (Phase II) | Dose Level 3 Dose (Flavopiridol 50 mg/m2 + 50 mg/m2) | Partial Response | 2 | patients | |
| Qualitative and Quantitative Toxicities in Regard to Organ Specificity | Dose Levels 1, 2, 3 | Leukopenia | 86 | percentage of patients | |
| Qualitative and Quantitative Toxicities in Regard to Organ Specificity | Dose Levels 1, 2, 3 | Neutropenia | 23 | percentage of patients | |
| Qualitative and Quantitative Toxicities in Regard to Organ Specificity | Dose Levels 1, 2, 3 | Infection | 20 | percentage of patients | |
| Qualitative and Quantitative Toxicities in Regard to Organ Specificity | Dose Levels 1, 2, 3 | Diarrhea | 51 | percentage of patients | |
| Qualitative and Quantitative Toxicities in Regard to Organ Specificity | Dose Levels 1, 2, 3 | Fatigue | 34 | percentage of patients | |
| Lymphoid/Plasma Cell Malignancies | Cohort 1 | Partial Response | 3 | patients | |
| Lymphoid/Plasma Cell Malignancies | Cohort 2 | Partial Response | 2 | patients | |
| Lymphoid/Plasma Cell Malignancies | Cohort 4 | Partial Response | 0 | patients |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00112723/results